Publications
2019
2018
The core value assessment for innovative pharmaceutical projects is the core work of product initiation, product licensing, investment, mergers and acquisitions in pharmaceutical industry. Multi-level analysis of core values of innovative medical projects from the aspects of unmet clinical needs, market capacity, competitive landscape, clinical success rate, data, intellectual property, and the implementation capacity of R&D team can help to evaluate the commercial prospects, innovation quality and the likelihood of future success of these projects, reducing the systematic risk in new drug R&D. The strategies of core value assessment for innovative pharmaceutical projects have been introduced in this paper.
创新性医药项目核心价值评估是医药行业产品立项、产品引进、投资并购的核心工作。从未满足临床需求、市场容量、竞争格局、临 床成功率、数据、知识产权、研发团队的推进能力等多层面分析创新性医药研发项目核心价值,可以判断该项目的未来商业化前景、创新水平 和质量、未来成功实现的可能性,从而降低新药研发的系统性风险。总结和介绍了创新医药项目核心价值评估的策略。
2017
The BET proteins are major transcriptional regulators and have emerged as new drug targets, but their functional distinction has remained elusive. In this study, we report that the BET family members Brd2 and Brd4 exert distinct genomic functions at genes whose transcription they co-regulate during mouse T helper 17 (Th17) cell differentiation. Brd2 is associated with the chromatin insulator CTCF and the cohesin complex to support cis-regulatory enhancer assembly for gene transcriptional activation. In this context, Brd2 binds the transcription factor Stat3 in an acetylation-sensitive manner and facilitates Stat3 recruitment to active enhancers occupied with transcription factors Irf4 and Batf. In parallel, Brd4 temporally controls RNA polymerase II (Pol II) processivity during transcription elongation through cyclin T1 and Cdk9 recruitment and Pol II Ser2 phosphorylation. Collectively, our study uncovers both separate and interdependent Brd2 and Brd4 functions in potentiating the genetic program required for Th17 cell development and adaptive immunity.